Subgroup analysis suggests that patients who are male, HBsAg-positive, have AFP ≤400 ng/mL, Child-Pugh A, multiple tumors, tumor size ≤5 cm, absence of portal vein thrombosis, and those receiving TACE benefit more significantly from the combination therapy. The gene discussed is AFP; the disease is Portal vein thrombosis.